{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:10:17Z","timestamp":1773112217787,"version":"3.50.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15799-5","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T03:55:17Z","timestamp":1772423717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of atezolizumab combined with bevacizumab-based chemotherapy in advanced malignancies: a systematic review and meta-analysis of randomized trials"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2146-5280","authenticated-orcid":false,"given":"Kimia","family":"Pakdaman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4062-1318","authenticated-orcid":false,"given":"Amirhossein","family":"Alizadeh-Nodehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5939-8765","authenticated-orcid":false,"given":"Amin Esmaeilnia","family":"Shirvani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2490-3538","authenticated-orcid":false,"given":"Amir Morteza","family":"Soleimani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4178-111X","authenticated-orcid":false,"given":"Sara","family":"Mohammadnia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1933-3715","authenticated-orcid":false,"given":"Kasra","family":"Pakdaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2981-879X","authenticated-orcid":false,"given":"Mohammad Hossein","family":"Asghari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2654-2169","authenticated-orcid":false,"given":"Pouyan","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"15799_CR1","unstructured":"World Health Organization. Cancer Today. 2022 [Cited November 1, 2025]; Available from: https:\/\/gco.iarc.fr\/today\/en"},{"key":"15799_CR2","doi-asserted-by":"publisher","unstructured":"Sahin TK, Rizzo A, Aksoy S, Guven DC. Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2024;16(10):1835. https:\/\/doi.org\/10.3390\/cancers16101835.","DOI":"10.3390\/cancers16101835"},{"issue":"11","key":"15799_CR3","doi-asserted-by":"publisher","first-page":"e2443198","DOI":"10.1001\/jamanetworkopen.2024.43198","volume":"7","author":"HM Bizuayehu","year":"2024","unstructured":"Bizuayehu HM, Ahmed KY, Kibret GD, Dadi AF, Belachew SA, Bagade T, et al. Global Disparities of Cancer and Its Projected Burden in 2050. JAMA Netw Open. 2024;7(11):e2443198.","journal-title":"JAMA Netw Open"},{"key":"15799_CR4","doi-asserted-by":"publisher","unstructured":"Guven DC, Sahin TK, Erul E, Kilickap S, Gambichler T, Aksoy S. The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022;14(11):2675. https:\/\/doi.org\/10.3390\/cancers14112675.","DOI":"10.3390\/cancers14112675"},{"issue":"6","key":"15799_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1200\/JCO.23.01751","volume":"42","author":"SH Armenian","year":"2024","unstructured":"Armenian SH, Chao C. Burden of Morbidity and Mortality in Adolescent and Young Adult Cancer Survivors. J Clin Oncol. 2024;42(6):735\u201342.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15799_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13048-024-01362-y","volume":"17","author":"I Barad\u00e1cs","year":"2024","unstructured":"Barad\u00e1cs I, Teutsch B, V\u00e1radi A, Bil\u00e1 A, Vincze \u00c1, Hegyi P, et al. PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials. J Ovarian Res. 2024;17(1):53.","journal-title":"J Ovarian Res"},{"issue":"11","key":"15799_CR7","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1158\/1535-7163.MCT-24-0703","volume":"24","author":"NM Zacharias","year":"2025","unstructured":"Zacharias NM, Ozambela M, Karki M, He R, Chauhan PK, Pesquera PI, et al. Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma. Mol Cancer Ther. 2025;24(11):1722\u201332.","journal-title":"Mol Cancer Ther"},{"key":"15799_CR8","doi-asserted-by":"publisher","first-page":"109334","DOI":"10.1016\/j.intimp.2022.109334","volume":"113Pt A","author":"A Ameri","year":"2022","unstructured":"Ameri A, Tavakoli-Far B, Rostami M, Abedi Kiasari B, Sakhaei D, Saad Ahmed O, et al. Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer. Int Immunopharmacol. 2022;113Pt A:109334.","journal-title":"Int Immunopharmacol"},{"key":"15799_CR9","doi-asserted-by":"publisher","first-page":"909027","DOI":"10.3389\/fimmu.2022.909027","volume":"13","author":"W Liu","year":"2022","unstructured":"Liu W, Huo G, Chen P. Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. Front Immunol. 2022;13:909027.","journal-title":"Front Immunol"},{"key":"15799_CR10","doi-asserted-by":"publisher","first-page":"102179","DOI":"10.1016\/j.eclinm.2023.102179","volume":"63","author":"AV Kulkarni","year":"2023","unstructured":"Kulkarni AV, Tevethia H, Kumar K, Premkumar M, Muttaiah MD, Hiraoka A, et al. Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. EClinicalMedicine. 2023;63:102179. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102179.","journal-title":"EClinicalMedicine"},{"issue":"11","key":"15799_CR11","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","volume":"16","author":"MA Socinski","year":"2021","unstructured":"Socinski MA, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, et al. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. J Thorac Oncol. 2021;16(11):1909\u201324.","journal-title":"J Thorac Oncol"},{"key":"15799_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103\u201312.","journal-title":"J Clin Epidemiol"},{"key":"15799_CR13","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.","journal-title":"BMJ"},{"issue":"2","key":"15799_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"1","key":"15799_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). 2021;112(1):90\u20132.","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"7","key":"15799_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s12032-025-02812-3","volume":"42","author":"NA Yusoh","year":"2025","unstructured":"Yusoh NA, Ahmad H, Vallis KA, Gill MR. Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies. Med Oncol. 2025;42(7):262.","journal-title":"Med Oncol"},{"issue":"2","key":"15799_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4103\/idoj.IDOJ_475_18","volume":"10","author":"B Nair","year":"2019","unstructured":"Nair B. Clinical Trial Designs. Indian Dermatol Online J. 2019;10(2):193\u2013201.","journal-title":"Indian Dermatol Online J"},{"issue":"6","key":"15799_CR18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.7326\/0003-4819-133-6-200009190-00014","volume":"133","author":"R Temple","year":"2000","unstructured":"Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000;133(6):455\u201363.","journal-title":"Ann Intern Med"},{"key":"15799_CR19","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"issue":"6","key":"15799_CR20","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785\u2013805.","journal-title":"Stat Methods Med Res"},{"key":"15799_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"15799_CR22","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. Available from www.cochrane.org\/handbook"},{"issue":"7414","key":"15799_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"11","key":"15799_CR24","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"issue":"6","key":"15799_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2188\/jea.15.235","volume":"15","author":"Y Hayashino","year":"2005","unstructured":"Hayashino Y, Noguchi Y, Fukui T. Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol. 2005;15(6):235\u201343.","journal-title":"J Epidemiol"},{"key":"15799_CR26","doi-asserted-by":"crossref","unstructured":"Masoumeh S. Chapter 12 - Publication bias and funnel plot. In: Mahsa G, Nima R, Sara H, editors. Systematic Review and Meta-Analysis. Academic; 2025. pp. 157\u201368.","DOI":"10.1016\/B978-0-443-13428-9.00012-4"},{"issue":"7650","key":"15799_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"issue":"10421","key":"15799_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","volume":"403","author":"A Oaknin","year":"2024","unstructured":"Oaknin A, Gladieff L, Mart\u00ednez-Garc\u00eda J, Villacampa G, Takekuma M, De Giorgi U, et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet. 2024;403(10421):31\u201343.","journal-title":"Lancet"},{"issue":"7","key":"15799_CR29","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","volume":"23","author":"C Antoniotti","year":"2022","unstructured":"Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022;23(7):876\u201387.","journal-title":"Lancet Oncol"},{"issue":"7","key":"15799_CR30","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1038\/s41591-025-03658-y","volume":"31","author":"C Zhou","year":"2025","unstructured":"Zhou C, Dong X, Chen G, Wang Z, Wu X, Yao Y, et al. Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial. Nat Med. 2025;31(7):2375\u201384.","journal-title":"Nat Med"},{"issue":"5","key":"15799_CR31","doi-asserted-by":"publisher","first-page":"100559","DOI":"10.1016\/j.esmoop.2022.100559","volume":"7","author":"J Tabernero","year":"2022","unstructured":"Tabernero J, Grothey A, Arnold D, de Gramont A, Ducreux M, O\u2019Dwyer P, et al. MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF(wt) metastatic colorectal cancer. ESMO Open. 2022;7(5):100559.","journal-title":"ESMO Open"},{"issue":"2","key":"15799_CR32","doi-asserted-by":"publisher","first-page":"e2149040","DOI":"10.1001\/jamanetworkopen.2021.49040","volume":"5","author":"NB Mettu","year":"2022","unstructured":"Mettu NB, Ou FS, Zemla TJ, Halfdanarson TR, Lenz HJ, Breakstone RA, et al. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(2):e2149040.","journal-title":"JAMA Netw Open"},{"issue":"24","key":"15799_CR33","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288\u2013301.","journal-title":"N Engl J Med"},{"issue":"17","key":"15799_CR34","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1200\/JCO.21.00306","volume":"39","author":"KN Moore","year":"2021","unstructured":"Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, et al. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050\/GOG 3015\/ENGOT-OV39). J Clin Oncol. 2021;39(17):1842\u201355.","journal-title":"J Clin Oncol"},{"issue":"5","key":"15799_CR35","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.annonc.2024.12.014","volume":"36","author":"E Felip","year":"2025","unstructured":"Felip E, Popat S, Dafni U, Ribi K, Pope A, Cedres S, et al. A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13\u201318 BEAT-meso trial. Ann Oncol. 2025;36(5):548\u201360.","journal-title":"Ann Oncol"},{"issue":"4","key":"15799_CR36","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s10147-025-02721-5","volume":"30","author":"Y Kato","year":"2025","unstructured":"Kato Y. Lenvatinib enhances antitumor immunity of anti-PD-1 antibody. Int J Clin Oncol. 2025;30(4):666\u201373.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"15799_CR37","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024;23(1):108.","journal-title":"Mol Cancer"},{"issue":"5","key":"15799_CR38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"15799_CR39","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1159\/000533166","volume":"12","author":"A Vogel","year":"2023","unstructured":"Vogel A, Finn RS, Blanchet Zumofen MH, Heuser C, Alvarez JS, Leibfried M, et al. Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis. Liver Cancer. 2023;12(6):510\u201320.","journal-title":"Liver Cancer"},{"issue":"4","key":"15799_CR40","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/23523735241296763","volume":"10","author":"MJ Moussa","year":"2024","unstructured":"Moussa MJ, Kovalenko I, Crupi E, Proskuriakova E, Geng Y, Fallara G, et al. Antiangiogenic therapy combined with immune checkpoint blockade in urothelial cancer: Systematic review and meta-analysis. Bladder Cancer. 2024;10(4):300\u201312.","journal-title":"Bladder Cancer"},{"issue":"1","key":"15799_CR41","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1186\/s12885-023-11112-w","volume":"23","author":"X Gao","year":"2023","unstructured":"Gao X, Zhao R, Ma H, Zuo S. Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis. BMC Cancer. 2023;23(1):635.","journal-title":"BMC Cancer"},{"issue":"11","key":"15799_CR42","doi-asserted-by":"publisher","first-page":"6780","DOI":"10.21037\/tcr-20-1975","volume":"9","author":"Q He","year":"2020","unstructured":"He Q, Li J, Zhang C, Tang S, Ren Q. The efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic drugs in renal cell carcinomas: a systematic review and meta-analysis. Transl Cancer Res. 2020;9(11):6780\u201391.","journal-title":"Transl Cancer Res"},{"issue":"25","key":"15799_CR43","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017;377(25):2500\u20131.","journal-title":"N Engl J Med"},{"issue":"11","key":"15799_CR44","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017;16(11):2598\u2013608.","journal-title":"Mol Cancer Ther"},{"key":"15799_CR45","doi-asserted-by":"publisher","first-page":"1036298","DOI":"10.3389\/fimmu.2022.1036298","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang L, Bai Y, Wang L, Ma X. Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1\/PD-L1 therapy. Front Immunol. 2022;13:1036298.","journal-title":"Front Immunol"},{"key":"15799_CR46","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/978-3-540-33177-3_33","volume-title":"Tumor Angiogenesis: Basic Mechanisms and Cancer Therapy","author":"RK Jain","year":"2008","unstructured":"Jain RK, Duda DG. Antiangiogenic Therapy for Normalization of Tumor Vasculature and Microenvironment. In: Marm\u00e9 D, Fusenig N, editors. Tumor Angiogenesis: Basic Mechanisms and Cancer Therapy. Berlin, Heidelberg: Springer Berlin Heidelberg; 2008. pp. 577\u201392."},{"issue":"1","key":"15799_CR47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020;52(1):17\u201335.","journal-title":"Immunity"},{"key":"15799_CR48","doi-asserted-by":"publisher","first-page":"12624","DOI":"10.1038\/ncomms12624","volume":"7","author":"JJ Wallin","year":"2016","unstructured":"Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624.","journal-title":"Nat Commun"},{"issue":"1","key":"15799_CR49","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.immuni.2013.07.005","volume":"39","author":"GT Motz","year":"2013","unstructured":"Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39(1):61\u201373.","journal-title":"Immunity"},{"issue":"43","key":"15799_CR50","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012;109(43):17561\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10189","key":"15799_CR51","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","volume":"393","author":"BI Rini","year":"2019","unstructured":"Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404\u201315.","journal-title":"Lancet"},{"issue":"2","key":"15799_CR52","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97\u2013111.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"15799_CR53","doi-asserted-by":"publisher","first-page":"2093518","DOI":"10.1080\/2162402X.2022.2093518","volume":"11","author":"P Liu","year":"2022","unstructured":"Liu P, Chen J, Zhao L, Hollebecque A, Kepp O, Zitvogel L, et al. PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. Oncoimmunology. 2022;11(1):2093518.","journal-title":"Oncoimmunology"},{"issue":"3","key":"15799_CR54","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrclinonc.2010.223","volume":"8","author":"L Zitvogel","year":"2011","unstructured":"Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8(3):151\u201360.","journal-title":"Nat Rev Clin Oncol"},{"key":"15799_CR55","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"issue":"6","key":"15799_CR56","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.12998\/wjcc.v12.i6.1050","volume":"12","author":"T Velikova","year":"2024","unstructured":"Velikova T, Krastev B, Gulinac M, Zashev M, Graklanov V, Peruhova M. New strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis. World J Clin Cases. 2024;12(6):1050\u201362.","journal-title":"World J Clin Cases"},{"key":"15799_CR57","doi-asserted-by":"publisher","first-page":"800879","DOI":"10.3389\/fimmu.2021.800879","volume":"12","author":"L Tang","year":"2021","unstructured":"Tang L, Wang J, Lin N, Zhou Y, He W, Liu J, et al. Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management. Front Immunol. 2021;12:800879.","journal-title":"Front Immunol"},{"issue":"12","key":"15799_CR58","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","volume":"96","author":"T Kamba","year":"2007","unstructured":"Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788\u201395.","journal-title":"Br J Cancer"},{"issue":"2","key":"15799_CR59","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","volume":"8","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Alekseev BY, et al. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. JAMA Oncol. 2022;8(2):275\u201380.","journal-title":"JAMA Oncol"},{"key":"15799_CR60","doi-asserted-by":"publisher","unstructured":"Dur\u00e1n-Pacheco G, Chandler GS, Maiya V, Socinski MA, Sonpavde G, Puente J, et al. Correlation of safety and efficacy of atezolizumab therapy across indications. J Immunother Cancer. 2024;12(11):e010158. https:\/\/doi.org\/10.1136\/jitc-2024-010158.","DOI":"10.1136\/jitc-2024-010158"},{"issue":"2","key":"15799_CR61","doi-asserted-by":"publisher","first-page":"57","DOI":"10.69854\/jcq.2024.0008","volume":"1","author":"T Yamane","year":"2024","unstructured":"Yamane T, Ta APD, Chu H, Chen H. The Risk Factors for Thyroid Immune-Related Adverse Events Requiring Medical Intervention. J Clin Question. 2024;1(2):57\u201366.","journal-title":"J Clin Question"},{"issue":"4","key":"15799_CR62","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.69854\/jcq.2025.0024","volume":"2","author":"Y An","year":"2025","unstructured":"An Y, Zu C, Zhuang X, Zheng X, Yasuda Y, Tang M. Emerging frontiers in the treatment of non-small cell lung cancer: innovations and clinical advances. J Clin Quest. 2025;2(4):e85.","journal-title":"J Clin Quest"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15799-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15799-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15799-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:04:24Z","timestamp":1773068664000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15799-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15799"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15799-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Due to nature of the study there is no need for publication concept.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"327"}}